Talquetamab
Talquetamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
21 项
全球在招研究
2 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Janssen Research & Development, LLC
- Stanford University
- Janssen-Cilag Ltd.
- SCRI Development Innovations, LLC
- Larysa Sanchez
- Christopher Strouse
- Naresh Bumma
- University of Leeds
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、丹麦、法国、德国、Greece、爱尔兰、Israel、意大利、挪威、西班牙、瑞典、英国
正在招募患者的 Talquetamab 研究
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
II 期招募中美国NCT06461988A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
不适用招募中丹麦法国德国GreeceNCT06285318Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
II 期招募中美国NCT05972135Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
II 期招募中美国NCT06827860A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
III 期招募中美国澳大利亚奥地利比利时NCT05552222A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
II 期招募中美国比利时中国法国NCT04634552Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
I 期招募中美国NCT07581704Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
II 期招募中美国NCT07657312Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
III 期招募中英国NCT07649525Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
I 期招募中美国NCT06348108Study on the Clinical Efficacy of Teclistamab and Talquetamab
不适用招募中比利时NCT06477783A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
II 期招募中美国NCT06066346A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
II 期招募中美国Brazil荷兰Puerto RicoNCT06500884Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
II 期招募中美国NCT06993675Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
II 期招募中美国NCT06100237GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
II 期招募中德国NCT05695508Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
II 期招募中丹麦Estonia挪威NCT06505369Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
II 期招募中意大利荷兰挪威西班牙NCT07107529Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
I 期招募中美国NCT07032714Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
I 期招募中美国NCT07093554The Norwegian Immunotherapy in Multiple Myeloma Study
不适用招募中挪威NCT06855121
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。